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The effects of empagliflozin on cardiorespiratory fitness in patients with type 2 diabetes mellitus
(T2DM) and heart failure with reduced ejection fraction (HFrEF) are unknown. In this pilot study
we determined the effects of empagliflozin 10 mg/d for 4 weeks on peak oxygen consumption
(VO2) in 15 patients with T2DM and HFrEF. As an exploratory analysis, we assessed whether
there was an interaction of the effects of empagliflozin on peak VO2 of loop diuretics. Empagli-
flozin reduced body weight (−1.7 kg; P = .031), but did not change peak VO2 (from
14.5 mL kg−1 min−1 [12.6-17.8] to 15.8 [12.5-17.4] mL kg−1 min−1; P = .95). However, patients
using loop diuretics (N = 9) demonstrated an improvement, whereas those without loop
diuretics (N = 6) experienced a decrease in peak VO2 (+0.9 [0.1-1.4] vs −0.9 [−2.1 to −0.3] mL
kg−1 min−1; P = .001), and peak VO2 changes correlated with the baseline daily dose of diuretics
(R = +0.83; P < .001). Empagliflozin did not improve peak VO2 in patients with T2DM and
HFrEF. However, as a result of exploratory analysis, patients concomitantly treated with loop
diuretics experienced a significant improvement in peak VO2.
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1 | INTRODUCTION
Sodium glucose co-transporter (SGLT)-2 inhibitors such as empagliflo-
zin and canagliflozin reduced the incidence of heart failure (HF) and
HF hospitalizations in clinical trials including patients with type 2 dia-
betes mellitus (T2DM).1,2 HF, like T2DM, is a chronic debilitating con-
dition, and is associated with impaired functional capacity and
reduced quality of life. The effects of SGLT-2 inhibitors on cardiore-
spiratory fitness (CRF) in patients with HF with reduced ejection frac-
tion (HFrEF) are unknown.3
In this pilot study (ClinicalTrials.gov Identifier: NCT02862067),
we hypothesized that empagliflozin would improve CRF, measured as
changes in peak oxygen consumption (VO2) at maximal cardiopulmo-
nary exercise test (CPX) in patients with HFrEF and T2DM. Patients
with T2DM and HFrEF share an exaggerated neurohormonal system
activation, in particular, of the renin-angiotensin-aldosterone system
(RAAS), which is a major driver of CRF and clinical outcomes in HFrEF,
independent of the blood pressure-lowering effects.4 By reducing glu-
cose reabsorption in the proximal renal tubules and increasing the
concentration of sodium at macula densa level, SGLT-2 inhibitors may
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prevent renin secretion and overall RAAS activation in response to
reduced sodium tubular levels. We therefore hypothesized that,
despite increased diuresis and natriuresis, empagliflozin would not fur-
ther activate the renin-angiotensin-aldosterone system (RAAS), known
to be involved in the pathophysiology of HFrEF.
Finally, as an exploratory analysis, we planned to determine
whether the effects of empagliflozin were influenced by concomitant
treatment with loop diuretics, agents also known to promote natriure-
sis and commonly used in HFrEF to manage symptoms.
2 | METHODS
2.1 | Cardiorespiratory fitness and physical activity
assessments
In this open-label single-arm prospective study, we assessed the
effects of empagliflozin on peak VO2 with CPX in 15 patients with
stable symptomatic HFrEF (New York Heart Association [NYHA] class
II-III, left ventricular EF [LVEF] < 50%) and T2DM (glycosylated
haemoglobin [HbA1c] 6.5%-10.0%) using a metabolic cart interfaced
with a treadmill and a conservative ramping protocol before and after
treatment with empagliflozin 10 mg daily for 4 weeks, in which speed
and grade were increased by approximately 0.6 estimated metabolic
equivalents (MET) every 60 seconds.5,6 Ventilatory gas analysis was
performed using a VMax Encore metabolic cart (Carefusion, Yorba
Linda, California) with a standard mouthpiece and nose clip setup. Cal-
ibration of the metabolic cart for volume and gas concentration was
obtained before every test. Ventilatory gas analysis measurements
were obtained for at least 3 minutes in the seated position before
beginning exercise, continuously throughout exercise, and 2 minutes
into the recovery period. Blood pressure (BP) was monitored with a
Tango exercise BP system (Suntech Medical, Morrisville, North Caro-
lina). BP measurements were monitored at rest, during exercise, and
during the recovery period. Resting BP was measured according to
clinical recommendations and using standardized methods. In brief,
patients rested in a seated position for at least 10 minutes; an appro-
priately sized brachial artery pressure cuff was used, and pressure was
measured with an automated device (Tango system, Suntech Medical,
Morrisville, North Carolina).
Peak VO2 is a strong independent predictor of events and is sen-
sitive for detecting the efficacy of therapeutic interventions in HF
patients.5 Importantly, peak VO2, measured by ventilatory expired gas
analysis, is not biased by overexertion, and is insensitive to the pla-
cebo effect.5,7
Physical activity was assessed using the International Physical
Activity Questionnaire-short version (IPAQ). The IPAQ-short is a
7-question questionnaire that estimates physical activity by assessing
responses to questions concerning duration and intensity of daily
physical activity.
2.2 | Cardiac function assessment
We assessed cardiac function using transthoracic Doppler echocardi-
ography to measure LV end-diastolic and end-systolic volume, LVEF,
early transmitral velocities (E) at pulsed wave Doppler spectra, early
mitral annulus velocities by tissue Doppler averaged between lateral
and septal (e0), and we calculated the E/e0 ratio.8,9
2.3 | Diuresis, natriuresis and RAAS activation
assessments
We assessed the effects of empagliflozin on 24-hour diuresis, urinary
sodium concentration (Na+UR) and RAAS activation, measured as
plasma renin activity (PRA), aldosterone plasma levels (ALD) and
ALD/PRA ratio, following overnight fasting and after suspension of
angiotensin II antagonists (ATII-A) and mineralocorticoid-receptor
antagonists (MRA) for 24 hours. Chemical laboratory analyses were
performed using clinical standard assays (LabCorp, Burlington, North
Carolina).
2.4 | Dietary sodium, body weight and waist
circumference assessments
Dietary sodium intake can affect fluid status and RAAS activation;
therefore, we estimated sodium intake using a standardized 5-pass
interview 24-hour dietary recall, as previously described.10 Body
weight and waist circumference were measured on the day of RAAS
activation assessment. Waist circumference was measured according
to the World Health Organization recommendations.11
2.5 | Statistical analysis
We used SPSS 24.0 (IBM Corp) for statistical analysis. Data are
reported as median and interquartile range for potential deviation
from the Gaussian distribution. Discrete variables are reported as a
number and percentage. Interval changes between baseline and
4 weeks in peak VO2 were analysed using the Wilcoxon test. Analysis
of interaction was assessed with a general linear model for repeated
measures for discrete variables or the Spearman correlation rank test
for continuous variables. Multivariate analysis using a linear regression
model was performed, using a stepwise approach including those vari-
ables associated with P < .05 at univariate analysis.
The Virginia Commonwealth University Institutional Review
Board approved the study, and all patients provided written informed
consent.
3 | RESULTS
3.1 | Baseline characteristics
Among the patients, 8 (53%) were women, 9 (60%) were White and
6 (40%) were Black Americans, median age was 60 (56-62) years, and
body mass index (BMI) was 34 (31-37) kg/m2. All patients were using
ATII-A; 7 patients (47%) were using MRA and 9 (60%) patients were
using loop diuretics. Median HbA1c was 7.8% (7.2-8.6), NTproBNP
was 229 pg/mL (47-657), creatinine was 1.1 mg/dL (0.9-1.2), esti-
mated glomerular filtration rate was 63 mL/min/1.73 m2 (63-88), PRA
was 5.4 ng/mL/h (2.5-20.0) and ALD was 9.3 ng/dL (6.8-13.7).
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Median peak VO2 was 14.5 mL kg
−1 min−1 (12.6-17.8) or 57%
(48-60) of predicted normative values.5 Median LVEF was 41%
(33-43), E/e0 was 10.9 (10.6-19.5) and e0 was 6.5 cm/s (5.5-7.4).
Median 24-hour urinary volume excretion was 1725 mL (1307-2354)
and median Na+UR was 72.5 mmol/L (64.9-110.8). Median dietary
sodium intake was 2869 mg (1701-3846).
3.2 | Body weight, fasting glycaemia, blood pressure
and cardiorespiratory fitness
In the overall cohort, treatment with empagliflozin for 4 weeks
increased 24-hour urine output (+43%; P = .007), reduced body
weight (−1.7 kg, P = .031), reduced resting diastolic blood pressure
(−8 mm Hg; P = .04) and led to a small, although statistically signifi-
cant, reduction in E/e’ ratio (from 10.9 [10.6-19.5] to 9.8
[8.3-16.9]; P = .035).
Empagliflozin did not, however, change peak VO2 relative to body
weight (from 14.5 [12.6-17.8] to 15.8 [12.5-17.4] mL kg−1 min−1;
P = .95) or when expressed in absolute values (from 1426
[1037-1672] to 1517 [1104-1726] mL min−1; P = .95) in the overall
cohort, nor did it change IPAQ-estimated physical activity (P = .59).
We found a large variability in changes in peak VO2, ranging from
−2.9 to +2.5 mL kg−1 min−1. None of the clinical variables, echocardio-
graphic LV parameters or changes in IPAQ-estimated physical activity
correlated with changes in peak VO2 with empagliflozin (all P > .05).
Moreover, neither the doses of ATII-A or MRA, nor the use of MRA,
influenced the changes in peak VO2 with empagliflozin. Importantly,
dietary sodium intake did not change during the overall duration of
the study (from 2869 [1701-3846] to 2571 [2098-3378] mg; P = .39).
Treatment with empagliflozin for 4 weeks did not affect fasting gly-
caemia (from 140 [129-220] to 144 [107-166] mg/dL; P = .16).
3.3 | Loop diuretic use and effects on peak VO2
A statistically significant interaction between loop diuretic use
(9 [60%]) and effects on peak VO2 was found, for both peak VO2 rela-
tive to body weight (Figure 1A) (P = .001) and absolute peak VO2
(P = .001), showing a dose-dependent relationship between diuretic
dose and peak VO2 changes (R = +0.83; P < .001) (Figure 1B), without
differences in physical activity and blood pressure changes between
the 2 groups (P = .28 and P = .77, respectively). The change in Na+UR
(Figure 1C) and in the ALD/PRA ratio also correlated positively with
changes in peak VO2 (R = +0.622; P = .023 and R = +0.52; P = 0.057,
respectively). Neither ATII-A nor MRA doses correlated with changes
in Na+UR, PRA or ALD/PRA (all P > .05).
When investigating potential contributors to peak VO2 changes
in the overall cohort, the statistically significant predictors at univari-
ate analysis were BMI, waist circumference, HbA1c and loop diuretic
dose, but diuretic dose remained the only significant predictor for
peak VO2 changes at multivariate analysis (β coefficient = .623;
P = .013).
A significant interaction between diuretic use and the effects of
empagliflozin on Na+UR was also found, showing a reduction in
Na+UR, a surrogate for renin activation12 in patients treated with
empagliflozin without loop diuretics, but not in those treated with
loop diuretics (−32% vs 0%, respectively; P = .031). We found a non-
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FIGURE 1 Greater peak oxygen
consumption (VO2) changes in patients
with heart failure and reduced ejection
fraction (HFrEF) receiving loop diuretics (A).
Baseline diuretic dose (B) and changes in
urinary sodium concentration (Na+UR)
(C) correlate with change in peak VO2.
Increased aldosterone (ALD)/renin ratio in
patients receiving loop diuretics (D). Panel
C excludes 2 patients not treated with
diuretic because of laboratory internal
issues for 24-hour urinary sodium
concentration measurement, possibly the
result of damaged samples. *diuretic use
limited to loop diuretic use and expressed
as furosemide-equivalent dose (mg/d)
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significant trend for PRA changes without and with diuretics (+50% vs
−22%, respectively; P = .21) and a significant interaction between use
of diuretics and the ALD/PRA ratio, a more accurate marker for renin
activation (decrease in ratio) vs aldosterone hypersecretion (increase)
(−66% vs +26%, respectively; P = .028) (Figure 1D). Finally, we found
a significant association between changes in resting diastolic BP and
aldosterone plasma level changes (R = −0.55; P = .03). However, nei-
ther systolic nor diastolic resting BP were associated with changes in
CRF (both P > .30).
4 | DISCUSSION
The data presented herein show, for the first time, that SGLT-2 inhibi-
tion with empagliflozin was associated with a highly heterogeneous
response in terms of peak VO2, Na
+UR, PRA and ALD/PRA that
depended on the presence or absence of concomitant loop diuretic
use. Although resulting from an exploratory analysis requiring confir-
mation in larger clinical trials, the combination of empagliflozin and
loop diuretics appears to have synergistic effects on diuresis, without
inducing RAAS activation, and resulting in an increase in Na+UR con-
centration, and in a significant increase in peak VO2. On the other
hand, the use of empagliflozin without loop diuretics induced a para-
doxical reduction in Na+UR, resulting in more diluted urine, possibly
as the result of RAAS activation, and in a lack of any improvement, or
even a reduction, in peak VO2. It is therefore possible that empagliflo-
zin improves CRF in patients concomitantly treated with loop diuretics
by reducing RAAS activation, which is well-known to be detrimental
in HFrEF, but also in T2DM. Inhibition of RAAS activation reduces
systemic vascular resistance, resulting in vasodilation, improved car-
diac output, improved ventilatory efficiency, increased natriuresis/
diuresis and improved CRF.4,13
Our study is however, limited by the small sample size and by the
absence of assessment of O2 delivery and/or utilization, which could
have also affected the overall results, including the absence of signifi-
cant improvements in fasting glycaemia. Specifically, that may be the
result of our study being underpowered to detect changes in fasting
glycaemia. However, we cannot exclude the possibility that the
effects of empagliflozin in patients with established HFrEF are less
pronounced than in non-HFrEF patients, or that it requires more time
to achieve a similar effect, clearly requiring further and larger studies,
specifically in the HFrEF population.14 Moreover, changes in CRF did
not simply reflect interval changes in physical activity which, however,
was estimated using a subjective questionnaire that may not be as
sensitive as other means such as accelerometers.
SGLT-2 inhibitors reduced HF-related events in randomized clini-
cal trials1,2 and in real-world data15; however, the effects of this class
in well-characterized patients with established HFrEF, and more spe-
cifically, the effects on peak VO2, remain unknown.
Here we report an interaction between empagliflozin and use of
loop diuretics in patients with HFrEF, an interaction that was interest-
ingly posited in a recent clinical trial.2,16 The implications would be
that the use of empagliflozin in HFrEF patients not treated with loop
diuretics may be less beneficial. If confirmed in larger studies
evaluating the role of SGLT-2 inhibitors, specifically in patients with
HFrEF, this could greatly influence the clinical applications of these
agents.
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